Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PM3023
- Development stage
- Unknown
- Lead developer
- Pumis Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PM3023 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target Claudin 18.2 (CLDN18.2), a tight junction protein frequently overexpressed in various solid tumors, particularly gastric and pancreatic cancers. The therapy involves the genetic modification of a patient's own T cells to express a CAR that specifically recognizes and binds to CLDN18.2-positive tumor cells, leading to targeted cytotoxicity. PM3023 is currently being evaluated in early-phase clinical trials in China for the treatment of advanced solid tumors, including gastric cancer, gastroesophageal junction cancer, and pancreatic cancer, that have failed standard therapies. The development is primarily led by academic institutions such as The First Affiliated Hospital of Zhengzhou University.
- Other names
- PM3023 injectionPM-3023 injectionPM 3023 injection
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on PM3023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PM3023.